망막분지정맥폐쇄에 합병된 황반부종에서 유리체강내 베바시주맙 주입과 격자광응고술 병합요법

이승민 ( Seung Min Lee ),변익수 ( Ik Soo Byon ),이지은 ( Ji Eun Lee ),엄부섭 ( Boo Sub Oum ) 한국안전학회(구 한국산업안전학회) 2003 International Journal of Safety Vol.2 No.1

목적: 망막분지정맥폐쇄로 인한 황반부종 환자에서 유리체강내 베바시주맙 주입술 단독요법과 격자광응고술과의 병합요법의 임상적결과를 비교하였다. 대상과 방법: 망막분지정맥폐쇄에 의한 황반부종으로 베바시주맙 주입술을 받은 환자의 의무기록을 후향적으로 분석하였다. 병합요법군과 단독요법군으로 나누어 술전과 술후 1, 2, 그리고 6개월에 교정시력 및 빛간섭단층촬영의 중심황반두께를 조사하고 황반부종의재발 빈도를 비교하였다. 결과: 총 49안 중 18안에서 술후 평균 1.2개월에 격자광응고술을 하였으며 31안은 광응고술을 시행하지 않았다. 시력은 병합요법군에서 술후 2, 6개월에, 단독요법 군에서 술후 1, 2, 6개월에 유의하게 향상되었고, 중심황반두께는 두 군 모두 술후 모든 시기에서 유의하게 감소하였으나, 시력과 중심황반두께에서 두 군 사이에 유의한 차이는 없었다. 주사 후 6개월간 황반부종의 재발은 단독요법군에서 14안(45%)으로 병합요법군의 3안(17%)에 비해 유의하게 많았다(p=0.046). 결론: 망막분지정맥폐쇄에서 베바시주맙의 유리체강내 주사와 병합하여 시행한 격자광응고술은 황반부종의 재발로 인한 반복적인 재 주입술을 줄일 수 있었다. Purpose: To evaluate clinical outcomes of a combined therapy of intravitreal bevacizumab and grid laser photocoagulation for macular edema in branch retinal vein occlusion (BRVO). Methods: In the present retrospective study, medical records of patients who were treated with intravitreal bevacizumab injection for macular edema due to BRVO were reviewed. The eyes were divided into 2 groups, the combined therapy group of intravitreal bevacizumab and grid laser photocoagulation, and the monotherapy group of intravitreal bevacizumab. Visual acuity and central subfield macular thickness were investigated at 1, 2 and 6 months. Recurrence rate was compared between the 2 groups. Results: Among 49 eyes, 18 eyes underwent macular grid photocoagulation and 31 eyes did not receive laser treatment. Laser photocoagulation was performed at 1.2 months after injection on average. Visual acuity improved significantly at 2 and 6 months in the combined therapy group, and at 1, 2 and 6 months in the monotherapy group. Macular thickness decreased significantly compared to baseline at all visits in both groups. There was no significant difference in visual acuity and foveal thickness between the 2 groups. Recurrence at 6 months was significantly less frequent in the combined therapy group (3 eyes, 17%) then in the monotherapy group (14 eyes, 45%, p = 0.046). Conclusions: Combined grid photocoagulation after intravitreal bevacizumab injection lowered the recurrence rate of macular edema complicated with BRVO. J Korean Ophthalmol Soc 2012;53(10):1458-1464

결절맥락막혈관병증에서 베바시주맙 주입술과 광역학치료와의 병합치료의 비교

이자균,이지웅,이지은,엄부섭,Ja Kyun Lee,MD,Ji Woong Lee,MD,Ji Eun Lee,MD,PhD,Boo Sub Oum,MD,PhD 대한안과학회 2010 대한안과학회지 Vol.51 No.5

Purpose: To compare the efficacy of photodynamic therapy (PDT) using verteporfin combined with intravitreal bevacizumab and bevacizumab monotherapy in polypoidal choroidal vasculopathy (PCV). Methods: Twenty-six eyes, diagnosed with PCV were reviewed retrospectively. They were divided into two groups: combined treatment (COMB) and bevacizumab monotherapy (BEV). Visual acuity, fluorescein angiography (FA) and indocyanine green angiography (ICG) results were reviewed to compare changes in the polypoidal vessels and the branching vascular networks. Results: Among 26 eyes of 26 patients, there were 12 eyes in the COMB group and 14 eyes in the BEV group. Follow-up periods were about 42 weeks and 48 weeks for the respective groups. In the COMB group, visual acuity improved from log MAR 0.92 to 0.56, whereas visual acuity in the BEV group changed only minimally from log MAR 0.98 to 0.97. In the COMB group, the polypoidal vessel resolved in six eyes. In the BEV group, the polypoidal vessel resolved in one eye. In the COMB group, the vascular network resolved in one eye, improved in ten eyes, and did not change in one eye. In the BEV group, the vascular network did not change in any of the 14 eyes. Conclusions: Combined treatment with PDT and intravitreal bevacizumab resulted in a more prolonged effect, induced the resolution of polypoidal vessels more effectively than did bevacizumab monotherapy, and is expected to reduce recurrence and retreatment. J Korean Ophthalmol Soc 2010;51(5):684-692

망막분지정맥폐쇄에 합병된 황반부종에서 유리체강내 베바시주맙 주입과 격자광응고술 병합요법

이승민,변익수,이지은,엄부섭,Seung Min Lee,Ik Soo Byon,Ji Eun Lee,Boo Sub Oum 대한안과학회 2012 대한안과학회지 Vol.53 No.10

Purpose: To evaluate clinical outcomes of a combined therapy of intravitreal bevacizumab and grid laser photocoagulation for macular edema in branch retinal vein occlusion (BRVO). Methods: In the present retrospective study, medical records of patients who were treated with intravitreal bevacizumab injection for macular edema due to BRVO were reviewed. The eyes were divided into 2 groups, the combined therapy group of intravitreal bevacizumab and grid laser photocoagulation, and the monotherapy group of intravitreal bevacizumab. Visual acuity and central subfield macular thickness were investigated at 1, 2 and 6 months. Recurrence rate was compared between the 2 groups. Results: Among 49 eyes, 18 eyes underwent macular grid photocoagulation and 31 eyes did not receive laser treatment. Laser photocoagulation was performed at 1.2 months after injection on average. Visual acuity improved significantly at 2 and 6 months in the combined therapy group, and at 1, 2 and 6 months in the monotherapy group. Macular thickness decreased significantly compared to baseline at all visits in both groups. There was no significant difference in visual acuity and foveal thickness between the 2 groups. Recurrence at 6 months was significantly less frequent in the combined therapy group (3 eyes, 17%) then in the monotherapy group (14 eyes, 45%, p = 0.046). Conclusions: Combined grid photocoagulation after intravitreal bevacizumab injection lowered the recurrence rate of macular edema complicated with BRVO. J Korean Ophthalmol Soc 2012;53(10):1458-1464

결절맥락막혈관병증에서 유리체강내 베바시주맙 주입술의 단기 효과

이민호,안진환,이지은,엄부섭,Min Ho Lee,Jin Hwan An,Ji Eun Lee,Boo Sub Oum 대한안과학회 2009 대한안과학회지 Vol.50 No.1

Purpose: To evaluate the short-term effect of intravitreal bevacizumab (Avastin<sup>Ⓡ) in polypoidal choroidal vasculopathy. Methods: Intravitreal Avastin<sup>Ⓡ was injected into 13 eyes of 13 patients with PCV in this retrospective, interventional case study. The follow-up period lasted over 3 months after therapy. Changes in best-corrected visual acuity (BCVA), foveal height determined by optical coherence tomography, and abnormal vasculature in indocyanine green angiography (ICGA) were evaluated. Results: The mean LogMAR BCVA was 0.82 at baseline, 0.78 at 1 month after treatment, and 0.73 at 3 months after treatment. Visual acuity was stabilized or improved in 13 eyes (100%). The mean foveal height was 288 μm at baseline, 231 μm (p<0.05) at 1 month after treatment, and 196 μm at 3 months after treatment. The polypoidal lesions in ICGA decreased in 4 eyes (31%), although branching vasculature in ICGA was unchanged in 13 eyes (100%). Conclusions: Intravitreal injection of Avastin<sup>Ⓡ may stabilize visual acuity and reduce macular edema due to decreased retinal pigment epithelial detachment and leaking. However, intravitreal injection had a minimal effect in occlusion of the symptomatic polypoidal lesions and no effect in occlusion of the branching vascular network.

삼출성 나이관련황반변성과 결절맥락막혈관병증에서 광역학치료와 베바시주맙 병합치료

이미현,구기홍,이지은,엄부섭,Mi Hyun Lee,MD,Gi Hong Gu,MD,Ji Eun Lee,MD,PhD,Boo Sub Oum,MD,PhD 대한안과학회 2011 대한안과학회지 Vol.52 No.7

Purpose: To compare the efficacies of photodynamic therapy (PDT) using verteporfin combined with intravitreal bevacizumab in choroidal neovascularization secondary to age-related macular degeneration and polypoidal choroidal vasculopathy (PCV). Methods: Photodynamic therapy followed by 3 monthly intravitreal injections of bevacizumab were performed for neovascular age-related macular degeneration (AMD group) and PCV (PCV group). The injections were performed within 2 weeks after PDT and then every 4 to 6 weeks. During the 12-month follow-up period, best-corrected visual acuity (BCVA), central subfield macular thickness (CSMT), and number of reinjections were reviewed retrospectively. Results: Out of 38 eyes, there were 21 eyes in the AMD group (mean age 66.8 years old) and 17 eyes in the PCV group (mean age 66.4 years old). The average follow-up duration was 17.0 months. At 12 months, the BCVA (logMAR) improved from 0.75 at baseline to 0.49 in the AMD group (p = 0.01) and from 0.81 to 0.63 in the PCV group (p = 0.03). The CSMT decreased significantly from 329 to 231 in the AMD group and from 354 to 223 in the PCV group. At 12 months, 20 eyes (95.2%) in the AMD group and 15 eyes (88.2%) in the PCV group increased or maintained BCVA. The numbers of reinjections were 4.3 in the AMD group and 3.0 in the PCV group. There were no significant differences in BCVA, BCVA changes, CSMT, or number of reinjection between the two groups. Conclusions: Combined PDT and intravitreal bevacizumab injections showed no significant difference in stabilization of vision or retreatment rates between neovascular age-related macular degeneration and PCV. J Korean Ophthalmol Soc 2011;52(7):816-824